Three experiments, three settings
Collagen in cultured cells
Maquart and colleagues, 1988. GHK-Cu increased collagen production in fibroblast cultures. These were human cells grown in a lab, not people having a skin treatment. The experiment didn't measure a complexion change or test GLOW.
Tendon healing in rats
Staresinic and colleagues, 2003. BPC-157 improved healing after rat Achilles tendons were cut. Strength and function were among the measures. It doesn't tell us whether a person with an ordinary injury would benefit from the blend.
Early safety of the whole thymosin protein
Ruff and colleagues, 2010. Healthy volunteers received full-length thymosin beta-4 into a vein. This was a short safety study, not a TB-500 trial. Its findings don't establish the safety of the fragment or GLOW.
Small studies and bigger questions
The two-person BPC-157 pilot
Lee and Burgess, 2025. This intravenous safety pilot involved two adults. Both had received BPC-157 into a vein before, and there was no comparison group. The study reported no observed adverse events, meaning health problems during the study, or measurable changes in checked blood markers. Two people can't establish the rate of uncommon problems, and the study didn't test GLOW.
The BPC-157 review
McGuire and colleagues, 2025. The review of BPC-157 research found little human evidence and called for well-designed trials. It treated the peptide as investigational, rather than an established treatment. That conclusion matters alongside encouraging animal findings.
The wider safety picture
Mendias and Awan, 2026. This review includes all three GLOW ingredients. It describes scarce rigorous human safety information. It's a review of peptide therapies, not a study showing that the combination is safe.
Specific safety questions
Hostynek and colleagues, 2011. Copper passed into and through human skin samples after GHK-Cu application. The work used tissue outside the body, not people with copper-handling conditions.
Hsieh and colleagues, 2017. BPC-157 encouraged blood-vessel growth in laboratory and animal work. This helps explain a theoretical concern about tumors' blood supply. It doesn't establish a human cancer outcome.
FDA information and access
FDA explains why compounding doesn't come with drug approval. The agency doesn't verify these preparations' safety, effectiveness or quality before marketing.
FDA's ingredient safety page, current as of April 22, 2026, separates withdrawn nominations from Category 2 entries. Safety concerns remain beside the withdrawn ingredients.
FDA's category list updated May 14, 2026 lists non-injectable GHK-Cu separately in Category 1. Category 1 isn't FDA approval; conditions apply to FDA's policy of holding off on enforcement.
HHS's telehealth licensure overview explains why the patient's location matters. It doesn't confirm a particular clinician's permission to practise or a service's coverage.